Based on these findings, and on the detrimental effects of BRD4 depletion on AML proliferation, many inhibitors targeting BET proteins have been designed and tested against several tumor types, including leukemia (Perez-Salvia and Esteller, 2017). The gene discussed is BRD4; the disease is acute myeloid leukemia.